NYLIM
CRL icon

New York Life Investment Management’s Charles River Laboratories CRL Stock Holding History

New York Life Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17M Buy
12,569
+1,432
+13% +$266K 0.02% 530
2025
Q4 		$2.22M Sell
11,137
-409
-4% -$74.2K 0.02% 514
2025
Q3 		$1.81M Sell
11,546
-160
-1% -$25.4K 0.02% 561
2025
Q2 		$1.78M Sell
11,706
-480
-4% -$64K 0.02% 552
2025
Q1 		$1.83M Buy
12,186
+48
+0.4% +$8.05K 0.02% 556
2024
Q4 		$2.24M Sell
12,138
-926
-7% -$178K 0.02% 526
2024
Q3 		$2.57M Sell
13,064
-496
-4% -$103K 0.03% 515
2024
Q2 		$2.8M Buy
13,560
+1,361
+11% +$308K 0.03% 469
2024
Q1 		$3.31M Buy
12,199
+5,066
+71% +$1.21M 0.03% 433
2023
Q4 		$1.69M Sell
7,133
-5,554
-44% -$1.09M 0.02% 573
2023
Q3 		$2.49M Buy
12,687
+2,909
+30% +$597K 0.03% 462
2023
Q2 		$2.06M Buy
9,778
+2,564
+36% +$510K 0.02% 504
2023
Q1 		$1.46M Buy
7,214
+19
+0.3% +$4.31K 0.02% 564
2022
Q4 		$1.57M Buy
7,195
+11
+0.2% +$2.4K 0.02% 558
2022
Q3 		$1.41M Buy
7,184
+27
+0.4% +$5.83K 0.02% 572
2022
Q2 		$1.53M Buy
+7,157
New +$1.75M 0.02% 556

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

New York Life Investment Management's CRL Position: Q1 2026 in Review

New York Life Investment Management increased its Charles River Laboratories (CRL) stake by 13% in Q1 2026, buying an estimated $266K and bringing the position to 12,569 shares worth $2.17M. The position accounts for 0.02% of the portfolio, ranked #530.

New York Life Investment Management first reported a position in CRL in Q2 2022 and has held it in 16 quarters since. The position peaked at $3.31M in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • New York Life Investment Management held 12,569 shares of Charles River Laboratories worth $2.17M as of Q1 2026.
  • New York Life Investment Management bought 1,432 Charles River Laboratories shares in Q1 2026, an estimated $266K.
  • Charles River Laboratories made up 0.02% of New York Life Investment Management's portfolio in Q1 2026, its #530 holding.
  • New York Life Investment Management first reported a position in Charles River Laboratories in Q2 2022 and has held it in 16 quarters since.
  • New York Life Investment Management's Charles River Laboratories position peaked at $3.31M in Q1 2024.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on New York Life Investment Management's 13F filing for Q1 2026, filed 7 May 2026.